A 32-year-old woman undergoes elective laparoscopic cholecystectomy under general anesthesia with sevoflurane and nitrous oxide. Anesthesia is maintained with propofol infusion and fentanyl. She has a history of motion sickness and previous postoperative nausea and vomiting (PONV) after cesarean delivery 2 years ago. On postoperative day 0, she develops severe nausea and vomiting 2 hours after emergence from anesthesia, unresponsive to a single dose of ondansetron 4 mg IV. What is the most appropriate next step in her management?

Explanation

## Approach to Refractory PONV **Key Point:** When a single antiemetic class fails, the next step is to add an agent from a **different pharmacological class** rather than repeat the same drug or escalate its dose. ### Why Dexamethasone (Option A) Is Correct Dexamethasone is a corticosteroid antiemetic that acts via a **different mechanism** than 5-HT₃ antagonists (ondansetron). It suppresses prostaglandin synthesis and modulates substance P/NK₁ pathways in the brainstem, providing synergistic antiemetic activity when combined with ondansetron. The ondansetron + dexamethasone combination is the most evidence-based rescue strategy for refractory PONV and is endorsed by the 2020 SAMBA consensus guidelines (Gan et al.). ### Multimodal Antiemetic Strategy | Strategy | Approximate Efficacy | |----------|---------------------| | Monotherapy (single agent) | ~60% | | Dual therapy (2 different classes) | ~80–85% | | Triple therapy (3 different classes) | >90% | **High-Yield:** Combining agents from different receptor classes is superior to escalating doses of a single agent. This patient already received a 5-HT₃ antagonist; adding a corticosteroid addresses a complementary pathway. ### Why the Other Options Are Incorrect - **Option B – Metoclopramide 10 mg IV:** Metoclopramide is a dopamine (D₂) antagonist with weak antiemetic efficacy. While it acts via a different receptor than ondansetron, its efficacy in established PONV is inferior to dexamethasone, and it carries a risk of extrapyramidal side effects. It is not the preferred second-line agent when dexamethasone is available. *(KD Tripathi, Essentials of Medical Pharmacology, 8e)* - **Option C – Repeat ondansetron 4 mg IV immediately:** Repeating the same drug from the same class immediately after failure is not evidence-based. 5-HT₃ receptors are likely already saturated; a repeat dose within a short interval adds no meaningful benefit and does not address alternative emetic pathways. - **Option D – Droperidol 1.25 mg IV:** Droperidol (a butyrophenone/D₂ antagonist) is an effective antiemetic but carries an FDA black-box warning for QTc prolongation and torsades de pointes. It is not the preferred first rescue agent when safer alternatives (dexamethasone) are available, though it remains an option in refractory cases. ### Risk Factors in This Patient (Apfel Score = 4/4) - Female sex (2–3× higher risk) - Non-smoker (implied; high-risk feature) - History of motion sickness (strong independent predictor) - Previous PONV (strong independent predictor) - Use of volatile anesthetic (sevoflurane) and nitrous oxide (both emetogenic) - Opioid use (fentanyl) **Clinical Pearl:** This patient scored maximum on the Apfel simplified risk score and should have received prophylactic multimodal antiemetics intraoperatively (e.g., dexamethasone 8 mg at induction + ondansetron 4 mg at end of surgery ± scopolamine patch). Post-failure rescue with a second agent from a different class is now the appropriate step. [cite: Gan TJ et al. Fourth Consensus Guidelines for the Management of PONV, Anesthesia & Analgesia 2020; Miller's Anesthesia 9e Ch 42; KD Tripathi Essentials of Medical Pharmacology 8e]